Fees and Other Consideration. 7.01 Reimbursement of Reservation Charges Each Month during the term of this Agreement, Counterparty shall reimburse Manager, as provided herein, by payment in immediately available funds for one hundred percent (100%) of the aggregate total of the reservation charges and reservation surcharges, attributable to the Capacity Release during the applicable Month, calculated on the basis of the contract rates paid to the Service Providers by Manager. Manager shall remit to Counterparty any and all pipeline refunds associated with the Capacity Release as set forth in Section 2.03.
Fees and Other Consideration. In return for the right to receive from Consultant a share of the Net Profits, and in reliance on Consultant's promise to provide the consulting services described in this Agreement in Section 3, Christopher Homes promises to pay to Consultant as a consulting fee xxxxxx xxx term of this Agreement one and one-half percent (1-1/2%) of all Sales Revenues. Consulting fees will be paid to Consultant concurrently with, and on a pro rata basis with fees paid to Christopher Homes pursuant to
Fees and Other Consideration. Referring Broker will earn a referral fee as outlined in Exhibit B. Both parties understand that upon referring a Sales Lead, all negotiations for the provision of BRIDGE services to the Sales Lead shall be conducted between BRIDGE and the Sales Lead.
Fees and Other Consideration. 5.1 RXi agrees to pay a one-time payment to Advirna of $350,000.00 (Three Hundred Fifty Thousand Dollars) (“Patent Issuance Fee”), within ten (10) days following the issue date of the first patent from the Patent Rights with Valid Claims, which would otherwise be infringed by a Royalty-Bearing Product. If a patent within the Patent Rights is issued for which RXI concludes it does not include any such Valid Claims, then RXi shall notify Advirna of that fact within thirty (30) days following RXi’s receipt of a Notice of Allowance for that patent. Such notice to Advirna shall recite a specific reason for concluding that the patent within the Patent Rights does not include a Valid Claim. If Advirna disputes RXi’s conclusions regarding the existence of a Valid Claim and if the parties are unable to resolve the matter within twenty (20) days thereafter, then Advirna may refer the matter to final and binding arbitration in Boston, Massachusetts, in accordance with the then commercial rules of the American Arbitration Association (“A.A.A.”). RXi and Advirna will be equally responsible for the payment of arbitrator’s fee and the filing fee with the A.A.A. and otherwise, each party shall be responsible for its own attorneys’ fees and costs, witness fees, travel, transcripts, expert testimony and the like, provided, however, that the arbitrator shall have the right, but not the obligation, to award the prevailing party its fees and expenses (including reasonable attorneys’ fees).
Fees and Other Consideration. The fees and other consideration provided for herein are in addition to the fees and other consideration which were due and payable on the Initial Closing Date, the Amended Closing Date and the Second Amended Closing Date.
Fees and Other Consideration. The fees and other consideration provided for herein are in addition to the fees and other consideration due and payable on the Final Term Funding Date pursuant to the Old Agreement.
Fees and Other Consideration. For providing the services set forth on Exhibit A, Consultant shall be entitled to receive a fee of $225 per hour for each hour wholly devoted to providing such services, payable as set forth below. Consultant will xxxx the Company in half hour increments. On the first day of each calendar month, Consultant agrees to deliver to the Company a statement of work performed during the previous month. Within 30 days of receipt of this statement, the Company shall pay Consultant for appropriately documented and approved consulting fees. All outstanding, unvested stock options held by Consultant as of the Effective Date (the “Options”) and issued under the Millendo Therapeutics, Inc. 2012 Stock Plan, as amended (the “2012 Stock Plan”) and the OvaScience, Inc. (now known as Millendo Therapeutics, Inc.) 2012 Stock Incentive Plan, as amended (the “2012 Stock Incentive Plan” and, together with the 2012 Stock Plan, the “Plans”) shall continue to vest while Consultant is a “Service Provider” to the Company. A Service Provider is an employee, director or consultant of the Company. Notwithstanding the terms of the Plans, the stock option grant notices and agreements governing the Options, any other documents or agreements between Consultant and the Company setting forth the terms or vesting conditions of the Options (including but not limited to Consultant’s employment agreement with the Company) and any actions of the Board of Directors governing the Options (together, the “Option Documents”), the Options will not be subject to any accelerated vesting upon a change in control or other corporate transaction involving the Company or upon any termination of Consultant’s employment or service, and this Agreement supersedes and replaces the terms of the Plans and the Option Documents with respect to any accelerated vesting rights, terms or conditions related to the Options.
Fees and Other Consideration
